

Amyris to Present April 15 at Paradigm Capital Biosynthesis Conference – Exploring the Most Disruptive Technology in the Cannabis Industry

EMERYVILLE, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that management will be presenting at the Paradigm Capital Biosynthesis Conference on April 15 in Toronto. The focus of the conference will be to explore the most disruptive technology in the cannabis industry. Amyris believes that with its proven commercial history and leading technology platform that it is well suited to leverage development and commercialization of high-purity cannabinoids at significantly reduced cost through fermentation.

Amyris will discuss its previously disclosed cannabinoid development, licensing and commercialization agreement containing \$300 million of R&D and milestone payments and a long-term royalty stream during the presentation and 1X1 investor meetings. Due to the format of this inaugural event, the presentation is not being webcast.

“We’re pleased to share our strategy and progress for cannabis at this conference. We have now completed in our labs the technical performance requirements for our first major milestone for our CBD collaboration and share the excitement of our partner and their commitment to market leadership by enabling some of the world’s leading brands to improve the health and wellness of consumers,” said John Melo, President & CEO of Amyris. “We are making very good progress on a solid quarter and we are on track to deliver on the objectives we communicated on our recent earnings call.”

About Amyris

Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise™ products and services across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as expected first quarter performance and the anticipated cost of fermentation-derived cannabinoids. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to Amyris's liquidity and ability to fund operating and capital expenses, risks related to potential delays or failures in development, production and commercialization of products, risks related to Amyris's reliance on third parties, and other risks detailed from time to time in filings Amyris makes with the Securities and Exchange Commission, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Amyris disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo and No Compromise are trademarks or registered trademarks of Amyris, Inc. in the U.S. and/or other countries.

Contact:

Peter DeNardo

Director, Investor Relations and Corporate Communications

Amyris, Inc.
+1 (510) 740-7481
investor@amyris.com

<https://investors.amyris.com/2019-03-27-Amyris-to-Present-April-15-at-Paradigm-Capital-Biosynthesis-Conference-Exploring-the-Most-Disruptive-Technology-in-the-Cannabis-Industry>